Cross-sectional study explores differences in biomarkers in fulminant and non-fulminant COVID-19 myo …

887550

Sumary of Cross-sectional study explores differences in biomarkers in fulminant and non-fulminant COVID-19 myocarditis:

  • COVID-19 predominantly causes respiratory illness but, in some cases, may also affect the cardiovascular system and cause myocarditis..
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to the angiotensin-converting enzyme 2 (ACE-2) receptor present on the surface of cardiac cells, which likely explains the direct cardiac involvement in COVID-19 patients..
  • Myocarditis and its clinical presentation in COVID-19 Myocarditis is an inflammatory disease that has both infectious and non-infectious etiologies..
  • The most severe type of myocarditis is fulminant myocarditis, which is predominantly caused by viral infections..
  • Fulminant myocarditis is characterized by severe and sudden inflammation of the myocardium that leads to cardiogenic shock, ventricular bradyarrhythmias or tachyarrhythmias..
  • Although the clinical presentation of COVID-19 patients with myocarditis varies greatly, the usual symptoms include chest pain, fatigue, acute heart failure, and cardiogenic shock..
  • Previous studies have reported increased levels of inflammatory markers including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), lactate, and procalcitonin..
  • Several electrocardiogram (ECG) abnormalities are seen in myocarditis patients ranging from PR depression and ST elevation to new-onset bundle branch block, brady- or tachyarrhythmias, and QT prolongation….

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close